HR and breast cancer: In a phase II clinical study (NCT01528345), dovitinib, when combined with fulvestrant, demonstrated promising clinical efficacy for the treatment of postmenopausal breast cancer patients who were HR+ and HER2- and who had progressed despite prior ET.